Ibrutinib covalently binds to the cysteine 481 (C481) residue of the BTK active site, irreversibly restraining the BCR signaling pathway, which contributes to reduced activation, migration, proliferation, and survival of CLL cells. Here, BCR is linked to B-cell chronic lymphocytic leukemia.